DERMENCI, Alpay,OWEN, Dafydd Rhys,WRIGHT, Stephen Wayne,BROWN, Matthew Frank,FENSOME, Andrew,YANG, Xiaojing,XING, Li Huang,HAYWARD, Matthew Merrill,GERSTENBERGER, Brian Stephen
申请号：
CR20180372
公开号：
CR20180372A
申请日:
2017.02.10
申请国别(地区):
CR
年份:
2018
代理人:
摘要：
A compound whose structure or salt is pharmaceutically acceptable, or a compound or salt is pharmaceutically acceptable, wherein a, a and a are independent, or C = O, C-R or N-R,Where R and R may be independent h, amino-nr7cor6, cor6, conr7r8, C1-C6 asphalt or hydroxy (C1-C6 asphalt),R may or may not exist, and exists when allowed by Valencia rules, and does not exceed a, a and a or C = O； R0 and R are independent h, Br, Cl, f or C1-C6 tar； R1 is h, C1-C6 tar or hydroxy (C1-C6 tar)；R2 is selected from the group consisting of H, C1-C6 tar, C1-C6 alcox and hydroxy (C1-C6 tar),Phenyl (C1-C6 tar),Thyroid, heteromorphic, heterocyclic, cor6, ocor6, cour6, nr7cor6, conr7r8 and - (CH2) N-W, wherein W is cyanide, hydroxy, c3-c8cyclododecane, so2n7r8 and so2-r9, R9 is C1-C6 tar, c3-c8cyclododecane, heterogeneous or heterogeneous； in each tar, cyclododecane, Aperiodicity or aperiodicity may not be replaced by halogenation, cyanogen, hydroxyl or C1-C6 asphalt； X is c-r3 or N, wherein R3 may be h or C1-C6 asphalt； R4 and R5 may be independent h, amino, C1-C6 asphalt or hydroxi (C1-C6 asphalt)；R6, R7 and R8 are each independently H, C1-C6 alkyl, C1-C4 alkoxy (C1-C6 alkyl) or C3-C8 cycloalkyl, said C1-C6 alkyl is optionally substituted with halo, CN or hydroxy； or R7 and R8, together with the atom attached to them, form a 5 or 6 member ring, wherein the ring is optionally substituted with halo, hydroxy, CN or C1-C6 alkyl； and n is 0, 1, 2 or 3. Treatment methods such as Janus kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents are also provided.Un compuesto que tiene la siguiente estructura o una sal de este aceptable desde el punto de vista farmacéutico, o un solvato aceptable desde el punto de vista farmacéutico de un compuesto o una sal aceptable desde el punto de vista farmacéutico, en donde A, A¿ y A¿¿ son independientemente O, C=O, C-R¿ o N-R¿¿, en donde R¿ y R¿¿ pueden ser indepen
